Option chain shows key data for High Sierra Technologies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for High Sierra Technologies.

High Sierra Technologies (OTC:HSTI) Stock, Option Chain

High Sierra Technologies Inc is a start-up that develops and expands its intellectual property portfolio with an emphasis on the recreational cannabis industry as well as the industrial hemp industry. The company owns two provisional patent applications for producing new and novel cannabis products.

Cannabis

News

Penny Stocks

Markets

HPCO

HSTI

Hempacco Co., Inc. (NASDAQ: HPCO) has entered into a joint venture agreement with High Sierra Technologies, Inc.

Hempacco And High Sierra Team Up In A Joint Venture To Launch Low Odor Hemp Smokables

HIGH SIERRA TECH by High Sierra Technologies Inc.

High Sierra Technologies Inc

Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Arhaus, presenting an average target of $12.25, a high estimate of $15.00, and a low estimate of $10.00. This upward trend is evident, with the current average reflecting a 0.33% increase from the previous average price target of $12.21.
<img src="https://www.benzinga.com/files/images/story/2025/1740664835_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Arhaus is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jonathan Matuszewski</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arhaus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Arhaus compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Arhaus's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Arhaus's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ARHS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Arhaus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Arhaus</h2>
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in a number of categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and eCommerce sales channels.
<h3>Unraveling the Financial Story of Arhaus</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Arhaus's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -2.18% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Arhaus's net margin is impressive, surpassing industry averages. With a net margin of 3.11%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.15%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Arhaus's ROA stands out, surpassing industry averages. With an impressive ROA of 0.83%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Arhaus's debt-to-equity ratio surpasses industry norms, standing at 1.63. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ARHS

Deep Dive Into Arhaus Stock: Analyst Perspectives (8 Ratings)

Ratings for Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Urban Outfitters, revealing an average target of $59.8, a high estimate of $65.00, and a low estimate of $54.00. Observing a 17.49% increase, the current average has risen from the previous average price target of $50.90. 
<img src="https://www.benzinga.com/files/images/story/2025/1740664826_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Urban Outfitters among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$59.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Urban Outfitters. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Urban Outfitters compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Urban Outfitters's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Urban Outfitters's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/URBN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Urban Outfitters analyst ratings.</a>
<h2>Discovering Urban Outfitters: A Closer Look</h2>
Founded in 1970, Philadelphia-based Urban Outfitters is an apparel and home goods retailer that operates more than 700 stores and e-commerce in the United States (87.5% of fiscal 2024 sales) and other regions. Its retail nameplates are Urban Outfitters, Free People, FP Movement, and Anthropologie. Retail accounted for 91% of fiscal 2024 revenue, but the firm also sells products through a wholesale operation, owns some restaurants, and operates a clothing rental and resale business called Nuuly (5% of sales). Urban Outfitters primarily markets to young adults and offers products in categories such as apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
<h3>Urban Outfitters's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Urban Outfitters displayed positive results in 3 months. As of 31 October, 2024, the company achieved a solid revenue growth rate of approximately 6.3%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Urban Outfitters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Urban Outfitters's ROE excels beyond industry benchmarks, reaching 4.48%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Urban Outfitters's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.35%, the company showcases efficient use of assets and strong financial health.
Debt Management: Urban Outfitters's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.47.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

URBN

Where Urban Outfitters Stands With Analysts

Throughout the last three months, 11 analysts have evaluated Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Harmony Biosciences Hldgs, revealing an average target of $60.82, a high estimate of $75.00, and a low estimate of $42.00. A 1.55% drop is evident in the current average compared to the previous average price target of $61.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1740664817_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Harmony Biosciences Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$75.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Harmony Biosciences Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Harmony Biosciences Hldgs compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Harmony Biosciences Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Harmony Biosciences Hldgs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HRMY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Harmony Biosciences Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Harmony Biosciences Hldgs</h2>
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
<h3>Harmony Biosciences Hldgs: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Harmony Biosciences Hldgs's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 19.51%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 24.58%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.88%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Harmony Biosciences Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.13% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Harmony Biosciences Hldgs's debt-to-equity ratio is below the industry average at 0.27, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HRMY

Demystifying Harmony Biosciences Hldgs: Insights From 11 Analyst Reviews

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) has outperformed the market over the past 10 years by 2.89% on an annualized basis producing an average annual return of 13.85%. Currently, TJX Companies has a market capitalization of $140.63 billion. 
Buying $100 In TJX: If an investor had bought $100 of TJX stock 10 years ago, it would be worth $364.06 today based on a price of $125.10 for TJX at the time of writing.
<h3>TJX Companies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740664815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning TJX Companies Stock In The Last 10 Years

Stifel analyst Mark Astrachan downgrades ARKO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKO#NASDAQ">ARKO</a>) from Buy to Hold and lowers the price target from $8.5 to $7.5.

Downgrades

Price Target

ARKO

Stifel Downgrades ARKO to Hold, Lowers Price Target to $7.5

WestPark Capital analyst Casey Ryan reiterates Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and maintains $2.22 price target.

Reiteration

INVZ

WestPark Capital Reiterates Buy on Innoviz Technologies, Maintains $2.22 Price Target

WIIM

Fomento Economico Mexicano S.A.B. De C.V.

Fomento Economico Mexicano shares are trading higher. The company reported Q4 financial results.

Retail investors are once again proving to be the backbone of <a href="https://www.benzinga.com/trading-ideas/long-ideas">the stock market</a>, stepping in to buy every dip. 
According to JPMorgan analyst Nikolaos Panigirtzoglou, hedge funds, after playing defense for much of 2024, are now quietly rebuilding their positions &#8211; especially in the Magnificent Seven (MAG 7) stocks.
<h2 class="wp-block-heading">Retail's Relentless Buy-The-Dip Fuels The Market</h2>
Despite recent market jitters, retail investors continue to &#8220;buy the dip.&#8221; pouring a massive $79 billion into equity ETFs so far in February, per JPMorgan's data. That's only slightly below January's $92 billion, reinforcing retail's role as the market's backstop.
One ETF in particular stands out &#8211; Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq-100, spiked on February 25th. This suggests retail traders are staying aggressive on high-growth tech names like Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44001229/us-stocks-likely-to-open-higher-after-nvidias-blowout-earnings-this-is-still-a-bull-market-says-expert">US Stocks Likely To Open Higher After Nvidia&#8217;s Blowout Earnings: &#8216;This Is Still A Bull Market,&#8217; Says Expert</a>
<h2 class="wp-block-heading">Hedge Funds Rebuilding Magnificent Seven Exposure</h2>
Institutional investors, especially hedge funds, were in risk-off mode through late 2024, cutting exposure to the MAG 7 stocks. But Panigirtzoglou's data shows they're now quietly rebuilding positions in these names, a bullish signal for investors tracking institutional flows.
Equity long/short hedge funds, which had low beta exposure in December, have ramped it up in 2025, indicating renewed confidence in growth stocks.
<h2 class="wp-block-heading">Leveraged ETFs: A Double-Edged Sword</h2>
While retail money has been a stabilizing force, leveraged equity ETFs have been fueling volatility. JPMorgan's data reveals these ETFs triggered $19 billion in negative flows over just three days, amplifying the recent market correction.
For traders, this highlights a key takeaway: leverage can cut both ways. 
While leveraged ETFs like ProShares UltraPro QQQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TQQQ#NASDAQ">TQQQ</a>) can magnify gains, they also accelerate sell-offs—something to watch in choppy markets.
<h2 class="wp-block-heading">Takeaway for Investors</h2>
Retail investors remain a powerful force, hedge funds are wading back into the MAG 7. 
But with leveraged ETFs swinging the market, expect more volatility ahead.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43816112/hedge-fund-shake-up-tiger-appaloosa-soros-outperform-buffett-icahn-ackman">Hedge Fund Shake-Up: Tiger, Appaloosa, Soros Outperform Buffett, Icahn, Ackman</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Broad U.S. Equity ETFs

Tech

ETFs

AAPL

MSFT

NVDA

TQQQ

February Fever: Retail Investors 'Buy-The-Dip' As Hedge Funds Rebuild Magnificent Seven Bets

Six Flags Entertainment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) shares <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">are trading slightly higher on Thursday.</a>
The merger of legacy Cedar Fair and legacy Six Flags occurred on July 1, 2024,<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43999354/six-flags-entertainment-corporation-reports-2024-fourth-quarter-results-provides-adjusted-ebitda-g" rel="noreferrer noopener"> after the&nbsp;second quarter&nbsp;close.</a>
Accordingly, the reported results presented in this earnings release reflect the financial results for the combined company from Sept. 30, 2024, through Dec. 31, 2024 (fourth quarter).
Quarterly sales of $687.31 million missed the street view of $700.52 million. The increase in net revenues reflects $324 million of the net revenues related to the legacy Six Flags operations added in the merger.
Adjusted EBITDA increased by $120 million to $209 million. The increase in Adjusted EBITDA included $113 million from legacy Six Flags operations and a $7 million increase from legacy Cedar Fair operations, including the impact of the fiscal quarter calendar shift.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/44004387/hormels-q1-earnings-fall-short-of-estimates-amid-lower-margins" rel="noreferrer noopener">Hormel Foods Q1 Earnings: Organic Sales Edge Higher, EPS Misses, FY25 Outlook Intact And More</a>
&#8220;We successfully achieved more than $50 million in gross cost synergies and drove meaningful improvement in guest satisfaction scores and higher guest demand,&#8221; said Six Flags President and CEO Richard A. Zimmerman.&nbsp;
Modified EBITDA margin increased 650 bps to 30.4% from the year-ago period. The combined company reported net loss of $2.76 per share in the fourth quarter.
The company exited the quarter with cash and equivalents worth $83.174 million.
Outlook: For 2025, Six Flags is targeting Adjusted EBITDA of $1.08 billion to $1.12 billion, exclusive of any portfolio optimization efforts.
&#8220;Our 2025 guidance reflects the strong progress we&#8217;ve made to date and our belief in the opportunities ahead as we execute our initiatives to drive higher levels of attendance and guest spending, while realizing cost synergies and maximizing operating efficiencies,&#8221; Zimmerman added.
Price Action: FUN shares are trading higher by 2.52% to $47.15 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43990066/bitcoin-ethereum-xrp-dogecoin-extend-decline-btc-at-80000-by-mid-april-trader-wonders" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Extend Decline: ‘BTC At $80,000 By Mid-April?,&#8217; Trader Wonders</a></li>
</ul>
Photo via Shutterstock.

Equities

Movers

General

Six Flags Entertainment Q4 Sales Miss Estimates, CEO Highlights Cost Synergies

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and maintains $25 price target.

HUMA

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) with a Buy and maintains $7 price target.

ALEC

HC Wainwright & Co. Reiterates Buy on Alector, Maintains $7 Price Target

Keurig Dr Pepper shares are trading lower. The company announced a secondary public offering of 73 million shares.

Stifel analyst Paul Matteis initiates coverage on Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Buy rating and announces Price Target of $11.

Initiation

CMPS

Stifel Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $11

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and maintains $32 price target.

CMPX

D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $32 Price Target

BlackRock TCP Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCPC#NASDAQ">TCPC</a>) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.37 by 2.7 percent. This is a 18.18 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $61.25 million which missed the analyst consensus estimate of $65.26 million by 6.15 percent. This is a 20.57 percent increase over sales of $50.80 million the same period last year.

Earnings

Earnings Misses

TCPC

BlackRock TCP Cap Q4 adjusted net investment income per share $0.36 Misses $0.37 Estimate, Total investment income $61.25M Miss $65.26M Estimate

WAVE

Eco Wave Power Initiates Infrastructure Enhancements For Portugal Wave Energy Project

HC Wainwright &amp; Co. analyst Arthur He downgrades LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) from Buy to Neutral and lowers the price target from $2 to $1.5.

LVTX

HC Wainwright & Co. Downgrades LAVA Therapeutics to Neutral, Lowers Price Target to $1.5

PDSB

PDS Biotechnology shares are trading lower after the company announced up to $22 million registered direct offering priced at-the-market under Nasdaq rules.

Piper Sandler analyst Arvind Ramnani maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Neutral and lowers the price target from $85 to $76.

PYPL

Piper Sandler Maintains Neutral on PayPal Holdings, Lowers Price Target to $76

Needham analyst Ryan MacDonald reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) from Hold to Hold.

Comments

High Sierra Technologies

High Sierra Technologies (HSTI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga